News
London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
2d
GlobalData on MSNGSK’s Blenrep combos approved for multiple myeloma in EUThe combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...
GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...
The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...
GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
And other biotech news brought to you by The Readout.
FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results